These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3859929)

  • 21. [Arabinosilcytosine in the treatment of acute leukemia (author's transl)].
    Pozzi D; Mori NS; Jamra M
    Rev Bras Pesqui Med Biol; 1974; 7(1):13-8. PubMed ID: 4532776
    [No Abstract]   [Full Text] [Related]  

  • 22. High-dose cytosine arabinoside therapy in acute non-lymphocytic leukemia.
    Preisler HD
    Eur J Cancer Clin Oncol; 1984 Feb; 20(2):297-300. PubMed ID: 6538493
    [No Abstract]   [Full Text] [Related]  

  • 23. Central nervous system toxicity of high-dose cytosine arabinoside.
    Barnett MJ; Richards MA; Ganesan TS; Waxman JH; Smith BF; Butler MG; Rohatiner AZ; Slevin ML; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):227-32. PubMed ID: 3925559
    [No Abstract]   [Full Text] [Related]  

  • 24. [Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
    Schmalzl F; Braunsteiner H
    Wien Klin Wochenschr; 1971 Jun; 83(25):452-6. PubMed ID: 5289111
    [No Abstract]   [Full Text] [Related]  

  • 25. Cytosine arabinoside and herpes zoster.
    Mann JR
    Lancet; 1971 Jul; 2(7716):166. PubMed ID: 4104494
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies on the cytotoxicity of cytosine arabinoside.
    Haanen C; Muus P; Raymakers R; Drenthe-Schonk A; Salden M; Wessels J
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):120-9. PubMed ID: 3892698
    [No Abstract]   [Full Text] [Related]  

  • 27. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
    Kawano F; Tejima Y; Tajima H; Lee SY; Shiozaki A; Nakai R; Chyosa M; Sawada T; Maeda Y; Mizokuni T
    Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
    [No Abstract]   [Full Text] [Related]  

  • 28. Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.
    Saito T; Asai O; Dobashi N; Yano S; Osawa H; Takei Y; Takahara S; Ogasawara Y; Yamaguchi Y; Minami J; Usui N
    J Infect Chemother; 2006 Jun; 12(3):148-51. PubMed ID: 16826348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cytosine arabinoside in the initial treatment of acute leukemia.
    Barnett MJ; Waxman JH; Richards MA; Ganesan TS; Bragman KS; Rohatiner AZ; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):133-8. PubMed ID: 3859927
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis].
    Masi M; Vivarelli F; Paolucci P; Vecchi V
    Minerva Pediatr; 1975 Sep; 27(28):1539-50. PubMed ID: 1101022
    [No Abstract]   [Full Text] [Related]  

  • 31. Neurotoxicity associated with systemic high-dose cytosine arabinoside.
    Nand S; Messmore HL; Patel R; Fisher SG; Fisher RI
    J Clin Oncol; 1986 Apr; 4(4):571-5. PubMed ID: 3457102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Complete remission achieved by high dose cytosine arabinoside therapy in the 4th relapse of AML].
    Sai M; Naganuma Y; Aoki I; Toyama K
    Rinsho Ketsueki; 1986 Jun; 27(6):952-5. PubMed ID: 3463813
    [No Abstract]   [Full Text] [Related]  

  • 33. [High-dose cytosine arabinoside therapy in refractory acute leukemia].
    Yorimitsu S; Takahashi I; Kitazima K; Kimura I; Hara M; Tokuda M
    Rinsho Ketsueki; 1984 Dec; 25(12):1941-6. PubMed ID: 6533329
    [No Abstract]   [Full Text] [Related]  

  • 34. [Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase].
    Martín-Aragonés G; Sanz MA; Martínez JA; Rafecas FJ; Gomis F; Lorenzo I; Sanz G; Marty ML
    Sangre (Barc); 1985; 30(1):15-21. PubMed ID: 3859023
    [No Abstract]   [Full Text] [Related]  

  • 35. [High-dose cytosine arabinoside and L-asparaginase in the treatment of refractory or recurrent acute non-lymphoblastic leukemia].
    Sanz MA; Borrego D; Martín-Aragonés G; Martínez JA; Lorenzo I; Sanz G; Sayas MJ; Jarque I; Pastor E; Rafecas J
    Sangre (Barc); 1987; 32(4):476-81. PubMed ID: 3660187
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of early acute nonlymphatic leukemia with low dose cytosine arabinoside.
    Moloney WC; Rosenthal DS
    Haematol Blood Transfus; 1981; 26():59-62. PubMed ID: 7033074
    [No Abstract]   [Full Text] [Related]  

  • 37. Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside.
    Caballero MD; González M; Cañizo MC; Orfao A; Nieto MJ; San Miguel JF
    Leukemia; 1992 Aug; 6(8):856-8. PubMed ID: 1640739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 39. Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse.
    Ettinger LJ; Biener R; Finklestein JZ; Kamalakar P; Jones GR; Avramis VI; Holcenberg JS
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):155-9. PubMed ID: 3859930
    [No Abstract]   [Full Text] [Related]  

  • 40. Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.
    Wells RJ; Feusner J; Devney R; Woods WG; Provisor AJ; Cairo MS; Odom LF; Nachman J; Jones GR; Ettinger LJ
    J Clin Oncol; 1985 Jul; 3(7):998-1004. PubMed ID: 3860629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.